1. Home
  2. CDT vs INBS Comparison

CDT vs INBS Comparison

Compare CDT & INBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CDT
  • INBS
  • Stock Information
  • Founded
  • CDT 2019
  • INBS 2016
  • Country
  • CDT United States
  • INBS United States
  • Employees
  • CDT N/A
  • INBS N/A
  • Industry
  • CDT Biotechnology: Pharmaceutical Preparations
  • INBS Medical Specialities
  • Sector
  • CDT Health Care
  • INBS Health Care
  • Exchange
  • CDT Nasdaq
  • INBS Nasdaq
  • Market Cap
  • CDT 11.1M
  • INBS 12.3M
  • IPO Year
  • CDT N/A
  • INBS N/A
  • Fundamental
  • Price
  • CDT $1.15
  • INBS $2.21
  • Analyst Decision
  • CDT
  • INBS
  • Analyst Count
  • CDT 0
  • INBS 0
  • Target Price
  • CDT N/A
  • INBS N/A
  • AVG Volume (30 Days)
  • CDT 8.8M
  • INBS 394.6K
  • Earning Date
  • CDT 03-04-2025
  • INBS 02-13-2025
  • Dividend Yield
  • CDT N/A
  • INBS N/A
  • EPS Growth
  • CDT N/A
  • INBS N/A
  • EPS
  • CDT N/A
  • INBS N/A
  • Revenue
  • CDT N/A
  • INBS $3,031,405.00
  • Revenue This Year
  • CDT N/A
  • INBS $280.88
  • Revenue Next Year
  • CDT N/A
  • INBS $126.26
  • P/E Ratio
  • CDT N/A
  • INBS N/A
  • Revenue Growth
  • CDT N/A
  • INBS 23.21
  • 52 Week Low
  • CDT $1.13
  • INBS $1.00
  • 52 Week High
  • CDT $392.00
  • INBS $5.63
  • Technical
  • Relative Strength Index (RSI)
  • CDT 31.53
  • INBS 57.70
  • Support Level
  • CDT $1.60
  • INBS $2.04
  • Resistance Level
  • CDT $3.70
  • INBS $2.75
  • Average True Range (ATR)
  • CDT 0.44
  • INBS 0.27
  • MACD
  • CDT 0.09
  • INBS 0.02
  • Stochastic Oscillator
  • CDT 0.78
  • INBS 51.79

About CDT Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by leading biopharmaceutical companies in order to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready in autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

About INBS Intelligent Bio Solutions Inc.

Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company business through two operating segments include Commercially available Intelligent Fingerprinting Products (IFPG or IFPG segment) and, Development Stage Biosensor Platform Technology (BPT segment).

Share on Social Networks: